Stockscreener 앱 받기
2.29
1.78%
0.04
시장 영업 전:
2.12
-0.17
-7.42%
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - TipRanks
Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan
Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World
Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy" - MarketBeat
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CFO at Context Therapeutics (CNTX) receives 275,000-share stock option grant - Stock Titan
Context Therapeutics (CNTX) CEO granted 815,000 stock options - Stock Titan
What is Context Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Target Return Focused Stock Picks - mfd.ru
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN
Is Context Therapeutics Inc. a potential multi bagger2025 Technical Patterns & Smart Money Movement Tracker - mfd.ru
Shorts Report: Is H2O America stock forming a triangle patternQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Geopolitics Watch: Whats the fair value of TMHC stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Profit Recap: What is Context Therapeutics Incs book value per shareJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Fund Flows: How does Context Therapeutics Inc perform in inflationary periodsEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
Earnings Report: Is Klaviyo Inc attractive for institutional investorsLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
How cyclical is Context Therapeutics Inc.’s revenue streamProfit Target & Real-Time Buy Signal Notifications - mfd.ru
Bank Watch: Does ABRPRD have pricing powerPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru
Will AGF A S (5IN) stock return to pre crash levelsQuarterly Growth Report & Smart Swing Trading Alerts - mfd.ru
ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka
Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail
SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka
Biotech firm Context Therapeutics lines up four investor conferences - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen - Defense World
Compass Therapeutics (NASDAQ:CMPX) Cut to “Sell” at Wall Street Zen - Defense World
Market Wrap: Is PARR forming a breakout pattern2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn
Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka
ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst - Meyka
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aug Spikes: What is Context Therapeutics Incs book value per share2025 Sector Review & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance
THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility - Meyka
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
TELA Bio Grants Equity to New Hires as Medtech Growth Push Continues - mychesco.com
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
Ideas Watch: How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - Sahm
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Sarepta Therapeutics, Inc. (SRPT) stock: surges after-hours ahead of key Phase 3 results webcast - parameter.io
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player - mychesco.com
AI Stocks: Can TRTX deliver consistent dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ: CNTX) Issues Equity Awards to Attract New Talent - MyChesCo
Aug PostEarnings: Is Context Therapeutics Inc. likely to announce a buyback2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Sandoz Group (OTCMKTS:SDZNY) versus Context Therapeutics (NASDAQ:CNTX) Head-To-Head Contrast - Defense World
emerging us stocks2025 Price Targets & Verified Technical Trade Signals - Bollywood Helpline
Ideas Watch: How does Context Therapeutics Inc perform in inflationary periodsMarket Trend Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - Barchart.com
Contineum Therapeutics Reports Phase 2 Trial Results - MSN
2.90%
2.73%
자본화:
|
볼륨(24시간):